MedTrace Logo

Optimizing the Interval Between Cycles of PRRT with 177lu-dotatate in Sstr2 Positive Tumors

NCT03454763 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 618

Last updated 2024-09-19

No results posted yet for this study

Summary

Randomized Phase II Trial in sstr2 Positive Tumors to Optimize the Interval Between Cycles of PRRT With 177lu-dotatate

Conditions

Interventions

DRUG

PRRT every 5 weeks

PRRT (radiolabelled somatostatin analogues) every 5 weeks for 5 cycles

DRUG

PRRT every 8-10 weeks

PRRT (radiolabelled somatostatin analogues) every 8-10 weeks for 5 cycles

Sponsors & Collaborators

  • Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

    lead OTHER

Principal Investigators

  • Maddalena Sansovini, MD · IRST IRCCS

  • Stefano Severi, MD · IRST IRCCS

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-26
Primary Completion
2025-01-31
Completion
2025-01-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03454763 on ClinicalTrials.gov